BioXcel Therapeutics, Inc. financial data

Symbol
BTAI on Nasdaq
Location
555 Long Wharf Drive, New Haven, CT
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 139 % -44.9%
Quick Ratio 3.14 % -56.9%
Debt-to-equity -140 % +39.6%
Return On Equity 54.1 % -69.4%
Return On Assets -134 % -0.34%
Operating Margin -5.96K % -30.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.6M shares -64.3%
Common Stock, Shares, Outstanding 6.62M shares -83.6%
Common Stock, Value, Issued 60K USD +50%
Weighted Average Number of Shares Outstanding, Basic 7.84M shares +212%
Weighted Average Number of Shares Outstanding, Diluted 7.84M shares +212%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 868K USD -63.9%
Research and Development Expense 25.8M USD -47.3%
Costs and Expenses 52.6M USD -53%
Operating Income (Loss) -51.7M USD +52.8%
Net Income (Loss) Attributable to Parent -51M USD +52.8%
Earnings Per Share, Basic -10 USD/shares +90.8%
Earnings Per Share, Diluted -10 USD/shares +90.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.4M USD -69%
Inventory, Net 506K USD -81.1%
Other Assets, Current 995K USD -39.4%
Assets, Current 25.2M USD -60.7%
Property, Plant and Equipment, Net 324K USD -48.5%
Operating Lease, Right-of-Use Asset 222K USD -58.7%
Other Assets, Noncurrent 87K USD 0%
Assets 25.8M USD -60.6%
Accounts Payable, Current 16.7M USD +25.9%
Employee-related Liabilities, Current 41K USD -98%
Accrued Liabilities, Current 5.09M USD -62.3%
Liabilities, Current 33.4M USD +22.3%
Liabilities 133M USD -4.49%
Retained Earnings (Accumulated Deficit) -677M USD -8.14%
Stockholders' Equity Attributable to Parent -108M USD -44.9%
Liabilities and Equity 25.8M USD -60.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12M USD +32%
Net Cash Provided by (Used in) Financing Activities 13.2M USD -50.4%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 6.62M shares -83.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.16M USD -87%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.6M USD -67%
Operating Lease, Liability 256K USD -58.5%
Depreciation 305K USD -2.24%
Lessee, Operating Lease, Liability, to be Paid 261K USD -59.7%
Property, Plant and Equipment, Gross 1.98M USD 0%
Operating Lease, Liability, Current 256K USD -29.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 65K USD -83.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5K USD -83.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 569M USD +3.19%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 3.4M USD -71.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%